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Abstract
Cancer anemia is classified as an anemia of chronic diseases, although
it is sometimes the first symptom of cancer. Cancer anemia includes a
hemolytic component, important in the terminal stage when even
transfused cells are rapidly destroyed. The presence of a chronic
component and the terminal complications of the illness limit studies
of the hemolytic component. A multifocal model of tumor growth was
used here to simulate the terminal metastatic dissemination stage
(several simultaneous inoculations of Walker 256 cells). The hemolyt-
ic component of anemia began 3-4 days after inoculation in 100% of
the rats and progressed rapidly thereafter: Hb levels dropped from 14.9
– 0.02 to 8.7 – 0.06 from days 7 to 11 (~5 times the physiologically
normal rate in rats) in the absence of bleeding. The development of
anemia was correlated (r2 = 0.86) with the development of other
systemic effects such as anorexia. There was a significant decrease in
the osmotic fragility of circulating erythrocytes: the NaCl concentra-
tion causing 50% lysis was reduced from 4.52 – 0.06 to 4.10 – 0.01
(P<0.01) on day 7, indicating a reduction in erythrocyte volume.
However, with mild metabolic stress (4-h incubation at 37oC), the
erythrocytes showed a greater increase in osmotic fragility than the
controls, suggesting marked alteration of erythrocyte homeostasis.
These effects may be due to primary plasma membrane alterations
(transport and/or permeability) and/or may be secondary to metabolic
changes. This multifocal model is adequate for studying the hemolytic
component of cancer anemia since it is rapid, highly reproducible and
causes minimal animal suffering.
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Introduction
Cancer anemia is usually classified as an
anemia of chronic diseases (ACD), but is
sometimes the first symptom to appear and
therefore not necessarily a chronic manifes-
tation of cancer (1-3). Cancer anemia in-
cludes a hemolytic component which mark-
edly increases in the final stage of the illness,
when even transfused red blood cells (RBC)
are rapidly destroyed (4,5).
The mechanisms underlying the hemolytic
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component are not well understood, and their
study is difficult because of the simulta-
neous presence of a chronic component, and
because of ethical difficulties, treatments
and other complications, particularly in the
terminal stages.
In experimental studies such as those
previously performed with the Walker 256
tumor inoculated at a single subcutaneous
(sc) site, the development of anemia showed
the general characteristics of ACD (5,6).
However, if instead of the usual unifocal
tumor growth model, the studies are initiated
using multifocal simultaneous tumor inocu-
lations (simulating the metastatic dissemina-
tion of the final stage), the systemic effects
of cancer, including anemia, appear rapidly
and synchronously in all animals (7,8). The
development of anemia under these condi-
tions is similar to that found in terminal
cancer patients, in which the rate of RBC
destruction is very high (4,9). This multifo-
cal model using the Walker 256 tumor there-
fore seems to be particularly suited for the
study of the hemolytic component of cancer
anemia.
In the present study, we examined the
time-course of the changes occurring in he-
moglobin levels (Hb) and RBC osmotic fra-
gility (OF) and correlated them with other
systemic effects of cancer such as anorexia.
The OF was studied in fresh whole blood
samples and in the same RBC after meta-
bolic stress (in vitro incubation at 37oC).
Material and Methods
Tumor and animals
The Walker 256 A tumor line was
kindly provided by Dr. Maria C. Cintra
Gomes, Department of Physiology, IB/
UNICAMP. The line originally came from
the National Cancer Institute Bank, Cam-
bridge, MA, USA. The tumor is currently
kept in the laboratory under liquid N2 and is
maintained through intraperitoneal or sc pas-
sages in rats.
Thirty-five 9-week-old male Wistar rats
were used. The animals were housed at con-
trolled temperature (21oC), on a 12-h light-
dark cycle and fed a commercial rat diet
(Labina/Purina, Campinas, SP, Brazil). The
rats were randomly divided into experimen-
tal (tumor) and pair-fed control groups of 20
and 15 animals, respectively. The tumor bear-
ers were allowed free access to food, while
the pair-fed controls were allowed to eat
only the amount ingested the day before by
the tumor bearers. Both had free access to
water. Tumor-bearing rats received four dor-
sal sc inoculations of 5 x 106 tumor cells
each in 0.25 ml of Ringer-lactate spaced at
least 1 cm apart. Healthy tumor cells with
98% viability (assessed by Trypan blue) were
obtained from the ascitic fluid of a donor rat.
Control rats received four identical inocula-
tions of vehicle only.
The general UKCCR guidelines for ani-
mal welfare were followed (10). One of the
authors was responsible for the daily clinical
evaluation of the animals. Somatic and vis-
ceral pain was explored by palpation and
gentle compression of the limbs and axillary,
inguinal, tumoral, peritoneal and thoracic
regions. No animal needed to be sacrificed
before the end of the experiment.
Experimental design
Before tumor inoculation, the rats were
anesthetized with ether and a 0.7-ml blood
sample was collected from the suborbital
plexus into 0.05 ml heparin (5000 IU/ml).
The tumor bearers were sacrificed on days 4,
7 and 11 (5, 5 and 10 rats, respectively) after
tumor inoculation, and the pair-fed controls
on days 5, 8 and 12 (5, 5 and 5 rats, respec-
tively). At sacrifice, the thorax was opened
under deep ether anesthesia and a large (~6
ml) blood sample was collected into 0.3 ml
of heparin, via direct heart puncture with an
18 G needle. All blood samples were used
for hemograms and OF determinations.
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Hemogram
Hemograms were performed using a Cell-
dyn 1600 apparatus and the results were
corrected for the relative volume of heparin
present in each blood sample.
Osmotic fragility and RBC incubation tests
Red blood cell OF was determined as de-
scribed by Dacie et al. (11). Packed RBC
obtained from tumor bearers and controls (0.2
ml, followed by a 5-min centrifugation at 978
g) at sacrifice were incubated for 4 h at 37oC
after resuspension in different media: a) RL
(1.0 ml of Ringer-lactate), b) RL + G (1.0 ml of
Ringer-lactate + 2 mg of glucose), c) PLa (1.0
ml of autologous plasma) and d) PLa + G (1.0
ml of autologous plasma + 1 mg of glucose).
After incubation, the OF was again deter-
mined. To facilitate data analysis the median
corpuscular fragility (MCF) was often used.
MCF has been defined as the NaCl concentra-
tion (g/l) causing 50% of RBC lysis (11).
Autopsy
Autopsies were performed on all tumor-
bearing rats. The tumors were dissected and
weighed, and special attention was paid to
the eventual presence of metastases, the in-
vasion of important tissues and bleeding.
Statistical analysis
The results are reported as means – SEM.
The statistical significance of the changes in
fresh blood was determined by the Student
paired t-test. The significance of the metabolic
stress studies was tested by ANOVA and by
the paired Student t-test (12).
Results
Tumor development
Tumors grew at all inoculated sites (4/
rat) and were palpable within 3 days. Their
mean weights were 2.8 – 0.2 g and 10.3 – 0.6
g on days 7 and 11, respectively.
Development of anemia
Figure 1 shows the time-course of the
changes in Hb and food intake during the
experiment. The Hb levels decreased rapidly
(P<0.001) in tumor bearers, dropping from
14.9 – 0.2 to 8.7 – 0.6 g/dl in the last 4 days
(1.55 g dl-1 day-1, about 5 times the normal
rate of RBC destruction in rats). The de-
crease in Hb levels was correlated with the
decrease in food intake: on days 4, 7 and 11
Hb levels decreased 2.3 – 2.1, 16.7 – 1.1 and
48.3 – 3.3%, while the respective average
food intake decreased 27, 34 and 72% (r2 =
0.86, P<0.001).
Osmotic fragility changes in fresh RBC
Figure 2 shows the OF curves of fresh
RBC from tumor bearers and pair-fed con-
trols, 4, 7 and 11 days after tumor inocula-
tion. A significant shift to the left was ob-
served in all tumor bearers (Figure 2A, B and
C) which, expressed in MCF, corresponded
to -0.25 – 0.04, -0.42 – 0.06 and -0.36 – 0.07
g/l, respectively (P<0.01 in all instances). In
the control rats there was a slight shift to the
left on day 4 but no changes on days 7 and 11
Figure 1 - Changes in the hemo-
globin levels and daily food in-
take of rats with multifocal in-
oculations of the Walker 256 tu-
mor and of their pair-fed con-
trols. The pair-fed control data
were shifted backwards one day
in order to cancel the method-
ological delay in the protocol
(see Material and Methods).
*Tumor-bearing and pair-fed
control animals.
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(Figure 2D, E and F).
Consistent with the changes in OF the
hemogram showed a decrease in median
RBC corpuscular volume, expressed as fl,
with values of 53.2 (range 53-54), 51.6 (range
51-52) and 50.0 (range 49-52) for tumor
bearers on days 4, 7 and 11 after tumor
inoculation, respectively (r2 = 0.77, P<0.001).
In the control group, the values were 51.6
(range 51-53), 51.8 (range 50-53) and 50.2
(range 49-52), respectively (r2 = 0.21, not
significant).
Another change observed on day 11 was
the decrease in the slope of the RBC OF
curves (Figure 2C). The maximal derivative
value, which corresponds to the maximal
percent variation in RBC lysis, induced by a
change of 0.5 g/l in NaCl concentration
dropped from 51.7 – 1.8% on day zero to
43.7 – 2.1% per 0.5 g/l on day 11 (-8.0 –
%
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Figure 2 - Osmotic fragility
curves for fresh RBC from rats
multifocally inoculated with
Walker 256 tumor (left) and for
the pair-fed controls (right) sacri-
ficed on days 4 (A and D), 7 (B
and E) and 11 (C and F) after
inoculation. Filled symbols: %
hemolysis. Open symbols: de-
rivative values (difference be-
tween two consecutive points
on the hemolysis curve). Broken
lines and circles: mean values
on day zero. Solid lines and in-
verted triangles: mean values on
the day of sacrifice. n.s.: Nonsig-
nificant.
-0.11 ± 0.02 g/l
(P<0.01)
n.s.
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2.1% per 0.5 g/l, P<0.01). Under the same
conditions the changes in the control group
were not significant, i.e., 52.0 – 2.4 to 48.0 –
1.0% per 0.5 g/l (-4.0 – 2.2% per 0.5 g/l).
Osmotic fragility after in vitro incubation
The sensitivity of RBC from tumor-bear-
ing rats and their pair-fed controls to the
metabolic stress induced by incubation at
37oC for 4 h was tested using Ringer-lactate
buffer as incubation medium and autologous
plasma with or without glucose addition.
This treatment caused only a small increase
in the MCF of RBC from the pair-fed con-
trols, whereas RBC from tumor bearers were
more sensitive to the stress, particularly 11
days after tumor inoculation when the in-
crease in MCF was marked and the differ-
ence, compared with the controls, was sig-
nificant for all incubation media tested (Fig-
ure 3).
Autopsy
There were no signs of bleeding or mac-
roscopic visceral metastases. Only some en-
larged regional lymph nodes were observed,
particularly in the retroperitoneum and
around the thymus, but in no instance were
neighboring tissues invaded.
Discussion
All rats rapidly and synchronously devel-
oped anemia and anorexia, the systemic ef-
fects characteristic of the final stage of can-
cer, after multifocal tumor inoculation. The
effects began 3-4 days after inoculation and
progressed rapidly thereafter, and would have
resulted in death 8-9 days later (7,8) if the
rats had not been sacrificed at fixed times
according to the experimental protocol. The
effects developed in the absence of compli-
cations such as bleeding, invasions or visible
metastases, as confirmed at autopsy. The
early onset, rapid course and magnitude of
the decrease in Hb levels in the tumor bear-
ers indicated an acute form of anemia which,
in the absence of bleeding, could only be
explained by the rapid destruction of RBC.
Based on the rate of decrease in Hb levels,
the RBC destruction in the final four days
was about five times the normal physiologi-
cal rate for this phenomenon.
The rapid progress of the anemia seen
with multifocal tumor inoculation is quite
different from the progress observed after
unifocal inoculation. Figure 4 shows unpub-
lished data (Vieira-Matos AN and Rettori O)
from our laboratory similar to those reported
by others using the unifocal Walker 256
model (5,13). The average results obtained
under these conditions suggest that this can-
cer causes moderate chronic anemia and
mild temporary anorexia. These conclusions
can be partially explained by the fact that in
this model the periodic transverse averaging
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Figure 3 - Effect of a 4-h incuba-
tion at 37oC on the osmotic fra-
gility of RBC from tumor-bearing
and pair-fed control rats in differ-
ent incubation media: RL:
Ringer-lactate; RL + G: Ringer-
lactate + glucose (2 mg/ml); PLa:
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Pair-fed
Tumor-bearing
820
Braz J Med Biol Res 33(7) 2000
A.A. Vido et al.
of data mixes values from groups of animals
at very different stages of the illness with
data from animals with still undetectable
homeostatic alterations. In addition, the ex-
clusion of animals that died at the end of the
experiment, together with the survival of
some resistant animals generates an artifact
that suggests an apparent improvement in
the illness condition. Guaitani et al. (13)
recognized these influences while studying
the anorexia induced by the Walker 256
tumor and suggested a different treatment of
the data, in which the independent variable
was changed. Instead of time, this author
proposed the use of the percentage of the
survived time. Using this approach, at the
time of death (100% of survived time) for
example, all animals in the group were to-
tally anorectic. A further improvement in the
handling of this problem was described by
Rettori et al. (7). The multifocal tumor mo-
del avoids all of these problems by synchro-
nizing the onset and progress of the systemic
effects of the final stage of cancer among the
individuals of the experimental group (7,8).
Under the latter conditions, the hemolytic
component of cancer anemia is of particular
importance as described for humans by
Hyman and Harvey in the early 50s (4).
These authors demonstrated what is gener-
ally recognized in oncology, namely, that in
terminal cancer patients even the half-life of
transfused RBC is markedly reduced, so that
frequent transfusions are of little help in
maintaining reasonable Hb levels.
The increased importance of the hemo-
lytic component of the anemia of terminal
cancer patients is probably associated with
metastatic dissemination. In this regard, the
multifocal inoculation model simulates the
terminal stage of cancer, with the advantage
of dissociating the hemolytic component of
anemia from the chronic complications that
mask it.
Changes in red blood cell osmotic fragility
induced by the Walker 256 tumor
The OF of fresh RBC reflects their ability
to take up water without lysis and is deter-
mined by their volume-surface area ratio
(11).
In the present study, the development of
acute anemia was accompanied by a de-
crease in the OF of RBC (a shift to the left in
the OF curves), indicating a reduction in the
volume of circulating erythrocytes. Indeed,
the blood count showed that the mean cor-
puscular volume of RBC from tumor-bear-
ing rats was significantly reduced compared
with control RBC. On the other hand, the
higher increases in MCF after a 4-h incuba-
tion at 37oC when compared with pair-fed
controls indicated that the RBC of tumor
bearers had an increased propensity to swell
during incubation, thus decreasing the resis-
tance to metabolic stress. This effect was
cumulative since it became marked only on
day 11 and was absent or slight on days 4 and
7. The complexity of the factors associated
with the changes in OF induced by this tu-
mor was further suggested by the reduction
in the slope of the OF curve on day 11.
Mechanisms involved in RBC alterations
The above results shed little light on the
molecular basis of the observed phenome-
non. Hereditary alteration in RBC glycolytic
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enzymes, such as pyruvate kinase deficiency,
is an example of how a primary alteration in
RBC metabolism is able to induce anemia
associated with a decrease in the volume
(decreased OF) and resistance to metabolic
stress (marked OF increase after incubation)
of fresh RBC. On the other hand, hereditary
and acquired membrane defects are also
known to decrease the RBC volume-surface
area ratio, and hence decrease the OF (11).
In contrast, the induction of cell volume
changes leads to important cellular meta-
bolic alterations (14) such that circulating
molecules of tumor and/or host origin, cyto-
kines or other effector molecules (15) acting
on RBC metabolism and/or its plasma mem-
branes may be involved in inducing the ob-
served phenomenon. This hypothesis is sup-
ported by observations that the tumor-in-
duced OF effects seen in the present study
may be reproduced under special conditions
by incubating normal RBC with plasma from
tumor anemic animals (Vieira-Matos AN
and Rettori O, unpublished results). A re-
duction in RBC OF in anemic tumor-bearing
mice has been reported, and may be caused
by structural alterations in the RBC (16). We
have also observed a marked decrease in
RBC OF associated with anemia in rats bear-
ing DMBA-induced mammary cancer
(Cavalcanti TC and Rettori O, unpublished
results).
Relevance of the present observations
The high correlation (r2 = 0.86) between
the development of anemia and other well-
known systemic effects such as anorexia
induced by cancer suggests the possibility of
a common molecular basis for the serious
homeostatic alterations occurring in the fi-
nal stage of cancer. Recent studies have
proposed an imbalance between catabolic
and anabolic hormones and cytokines of
tumor and/or host origin as the molecular
basis for cancer cachexia (15). A main role
has been suggested for the following cyto-
kines: IL-a, IL-ß, IL-6, IL-8, TNF-a, INF-a
and g, but conclusive data are often lacking
(17,18), and because the circulating levels
usually do not correlate well with cachexia,
an alternative model of abnormal general-
ized high local production of cytokines
through positive feedback systems has been
proposed (17).
The possibility should be explored that
the study of the alterations in the RBC plasma
membrane and/or metabolism could help to
identify these molecules and to explain the
mechanism of cancer anemia, cachexia and
the so-called multiple organ failure syndrome,
frequently referred to as the cause of death in
cancer patients.
The multifocal tumor inoculation model
The explanation as to why several small
tumors (little more than 100 mg each on days
3-4) were more effective in inducing the
systemic effects of cancer than a single large
tumor (sometimes 40 g or more) is probably
related to the cell kinetics of tumor growth.
Studies in this field suggest that the sum of
proliferative tumor cells (PTC) in several
small tumors is larger and increases faster
than that of a single, big tumor, in which
most cells are non-proliferative (NPTC).
Recent work has demonstrated that in tu-
mors of up to 100 mg (days 3-4 in our model)
about 90% of the mass would be PTC and
would grow fast (exponentially), but they
would rapidly reach an almost steady state of
about 1-2 g (19). One explanation for this,
consistent with the current concepts of tu-
mor cell proliferation (20), would be that,
due to the rapidly increasing irrigation defi-
cit, about half of the new cells formed after
each replication would stay in G1 or go to G0,
with many of the latter progressing to apop-
tosis or necrosis. Thus tumors larger than 1-
2 g would grow mainly at the expense of
NPTC, i.e., cells that are not effective in
inducing the systemic effects of cancer. In
the final stage, when metastatic dissemina-
822
Braz J Med Biol Res 33(7) 2000
A.A. Vido et al.
tion occurs, the multiple small foci of neo-
plastic growth, each bearing high relative
populations of PTC, would produce a high
enough total rate of PTC growth to induce
the serious homeostatic alterations that cul-
minate in host death.
In addition to the already mentioned ad-
vantages of the multifocal model (synchro-
nism among individuals, rapidity, reproduc-
ibility and absence of complications), this
model also involves minimal animal suffer-
ing.
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